Holen Sie sich die Stockscreener-App
10.97
0.99%
-0.11
Schlusskurs vom Vortag:
$11.08
Offen:
$10.94
24-Stunden-Volumen:
1.42M
Relative Volume:
1.81
Marktkapitalisierung:
$684.71M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-4.9864
EPS:
-2.2
Netto-Cashflow:
$-8.40M
1W Leistung:
-12.80%
1M Leistung:
+17.58%
6M Leistung:
-12.80%
1J Leistung:
+32.97%
1-Tages-Spanne:
$10.82
$11.50
1-Wochen-Bereich:
$10.76
$12.85
52-Wochen-Spanne:
$8.15
$30.96
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.97 | 684.71M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLP - Defense World
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest - Defense World
Immunome, Inc. (NASDAQ:IMNM) Short Interest Update - MarketBeat
Long Term Trading Analysis for (IMNM) - Stock Traders Daily
Immunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha
The Manufacturers Life Insurance Company Sells 1,437 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Intech Investment Management LLC Takes $219,000 Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Janus Henderson Group PLC Purchases 324,614 Shares of Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Cerity Partners LLC Has $776,000 Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Where are the Opportunities in (IMNM) - Stock Traders Daily
Immunome Grants Stock Options to 15 New Hires in Workforce Expansion - StockTitan
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian
President of Immunome Picks Up 24% More Stock - Simply Wall St
Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock By Investing.com - Investing.com Australia
Immunome Inc (IMNM) CEO Clay Siegall Increases Stake with Signif - GuruFocus.com
Insider Buying: Robert Lechleider Acquires Shares of Immunome In - GuruFocus.com
Immunome, Inc. (NASDAQ:IMNM) CTO Acquires $198,030.00 in Stock - MarketBeat
Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Purchases 66,057 Shares of Stock - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Insider Acquires $149,831.40 in Stock - MarketBeat
Philip Tsai, CTO of Immunome, buys $198,030 in company stock By Investing.com - Investing.com South Africa
Philip Tsai, CTO of Immunome, buys $198,030 in company stock - Investing.com India
Immunome CEO Clay Siegall acquires $962,181 in company stock By Investing.com - Investing.com Nigeria
Immunome CEO Clay Siegall acquires $962,181 in company stock - Investing.com India
(IMNM) Investment Analysis and Advice - Stock Traders Daily
Immunome files to sell 1.8M shares of common stock for holders - TipRanks
Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Victory Capital Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for Immunome - MarketBeat
Wedbush Has Bullish Outlook for Immunome FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - Defense World
Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World
Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World
T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com
Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada
Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat
Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Option Exercise |
1.05 |
42,000 |
44,100 |
61,856 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Sale |
16.01 |
14,380 |
230,224 |
47,476 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):